[opensourcepharma] a open source cure for Ebola?

Wed Aug 13 18:23:55 UTC 2014

The Limits of the Patent System Do Patents Kill Innovation?

http://osddbengaluru.net/osdd/?p=16504

On Wed, Aug 13, 2014 at 10:27 PM, zakir thomas <zaksthomas at gmail.com> wrote:

> Hi
> My new blog is on the limits of patent system to drive innovation:
> http://innovip.blogspot.in/2014/08/the-limits-of-patent-system.html
> Zakir
>
>
> On Tue, Aug 12, 2014 at 9:37 PM, Richter, Melinda [JRDUS] <
> MRicht23 at its.jnj.com> wrote:
>
>>  You all may have seen this already, but in case not:
>>
>>
>>
>> *FACTBOX-Developers of potential Ebola vaccines and treatments*
>>
>> 11 August 2014 14:28 EDT
>>
>> Aug 11 (Reuters) - Several companies with potential Ebola vaccines and
>> treatments have captured the spotlight, as developers face mounting
>> pressure to expedite research on new medical interventions.
>>
>> The Ebola epidemic in West Africa has killed nearly 1,000 people and
>> prompted the World Health Organization to declare an international health
>> emergency.
>>
>> No Ebola drugs or vaccines have entered mid-stage human trials, let alone
>> been approved. The most advanced have been tested only in monkeys and a
>> handful of humans.
>>
>> VACCINES
>>
>> GLAXOSMITHKLINE PLC
>>
>> GSK is co-developing a vaccine with the U.S. National Institute of
>> Allergy and Infectious Diseases (NIAID), which has shown promising results
>> in primates.
>>
>> The vaccine is due to enter early-stage human trials, pending U.S. Food
>> and Drug Administration approval. GSK has said human testing should start
>> this year. NIAID expects trials to begin "as early as fall 2014."
>>
>> Even if it is fast-tracked and works as well as hoped, the new vaccine
>> could not be ready for widespread deployment before 2015.
>>
>> JOHNSON & JOHNSON
>>
>> The company's Crucell unit is working with the U.S. NIAID to develop a
>> vaccine, which should enter early-stage clinical testing in late-2015 or
>> early-2016. The Crucell vaccine is designed to give additional protection
>> against Marburg, another severe and highly fatal disease caused by a virus
>> from the same family as Ebola.
>>
>> BAVARIAN NORDIC A/S
>>
>> The Danish company is developing its smallpox vaccine, Imvanex, for use
>> as an anti-filovirus injection. The drug was found to be 100 percent
>> protective against Ebola and Marburg in non-human primates.
>>
>> The U.S. government awarded the company a $17.9 million contract in 2012.
>> The injectable form of Imvanex is likely to enter Phase I clinical trials
>> in the United States in 2015, Maxim analyst Jason Kolbert said.
>>
>> PROFECTUS BIOSCIENCES INC
>>
>> The privately owned company has tested its vaccine in monkeys, with good
>> results. A single intramuscular injection was found to protect all of the
>> rhesus monkeys exposed to Ebola three weeks later. The company hopes to
>> launch a human trial within 12 months.
>>
>> TREATMENTS
>>
>> TEKMIRA PHARMACEUTICALS CORP
>>
>> The FDA has allowed the Canadian drugmaker to resume testing a drug in
>> people infected with Ebola, after blocking human tests last month. The FDA
>> had halted the early-stage study following safety concerns among people
>> taking the highest doses of the drug.
>>
>> BIOCRYST PHARMACEUTICALS INC
>>
>> The company's BCX4430 drug is in pre-clinical trials to treat Marburg,
>> and analysts believe it could potentially cure Ebola.
>>
>> SIGA TECHNOLOGIES INC
>>
>> The bio-defense drug developer's experimental drug, ST-383, aims to
>> prevent the Ebola virus from entering host cells, effectively ending its
>> replication cycle, Kolbert said in a note. The company says the drug is
>> being tested on animals.
>>
>> MEDIVECTOR
>>
>> The privately held drugmaker, along with its Japanese partner, Fujifilm
>> Holdings Corp, is in talks with the FDA to submit an application to expand
>> the use of its influenza drug, Favipiravir, as a treatment for Ebola.
>>
>> SAREPTA THERAPEUTICS INC
>>
>> Sarepta has undertaken some human trials on its anti-Ebola drug, but lost
>> government funding two years ago.
>>
>> MAPP BIOPHARMACEUTICAL INC
>>
>> The California-based privately owned company shot into the limelight when
>> its anti-Ebola drug was given to two Ebola-infected U.S. aid workers, who
>> have since shown signs of improvement. However, so far it has only been
>> tested in monkeys. Mapp was part of a consortium of 15 research outfits
>> that in March won a five-year grant from the National Institutes of Health
>> worth up to $28 million to find a treatment for Ebola.
>>
>> NANOVIRICIDES INC
>>
>> The company said last week it would resume development of its anti-Ebola
>> drug. (Reporting by Natalie Grover in Bangalore)
>>
>>
>>
>> jjn1
>>
>>
>>
>> (c) Copyright Thomson Reuters 2014. Click For Restrictions -
>> http://about.reuters.com/fulllegal.asp
>>
>>
>> [image:
>> https://iwidget.infodesk.com/infodisplay/images/poweredby_bktext.gif]
>> <http://www.infodesk.com/>
>>
>>
>>
>>
>>
>> *MELINDA RICHTER | Head of Janssen Labs*
>>
>>
>>
>> [image: cid:image002.png at 01CE8EB4.BF3F57A0]
>>
>> 858.242.1501
>>
>>
>>
>>
>>
>> *From:* opensourcepharma [mailto:opensourcepharma-bounces at lists.okfn.org]
>> *On Behalf Of *zakir thomas
>> *Sent:* Tuesday, August 12, 2014 1:48 AM
>> *To:* Tomasz Sablinski
>> *Cc:* opensourcepharma at lists.okfn.org
>>
>> *Subject:* Re: [opensourcepharma] a open source cure for Ebola?
>>
>>
>>
>> There is this broad US patent (
>> http://www.google.com/patents/US20120251502 )covering ebola virus:
>>
>> Reproducing Claim 1 and 2 below:
>>
>> Zakir
>>
>>
>>
>> Claims
>>
>> *1*. An isolated hEbola virus comprising a nucleic acid molecule
>> comprising a nucleotide sequence of:
>>
>> a) a nucleotide sequence set forth in SEQ ID NOS: 1 or 10;
>>
>> b) a nucleotide sequence hybridizing under stringent conditions to SEQ ID
>> NOS: 1 or 10; or
>>
>> c) a nucleotide sequence of at least 70%-99% identity to the SEQ ID NOS:
>> 1 or 10, with the proviso that said nucleotide sequence is not SEQ ID NO:
>> 20.
>>
>> *2*. An isolated hEbola virus having Centers for Disease Control Deposit
>> Accession No. 200706291.
>>
>> *3*. The hEbola virus of claim 1 which is killed.
>>
>> *4*. The hEbola virus of claim 1 which is an attenuated hEbola virus.
>>
>> *5*. The virus of claim 4 wherein at least one property of the
>> attenuated hEbola virus is reduced from among infectivity, replication
>> ability, protein synthesis ability, assembling ability or cytopathic effect.
>>
>>
>>
>> On Fri, Aug 8, 2014 at 5:57 PM, Tomasz Sablinski <
>> tomasz at transparencyls.com> wrote:
>>
>> A good idea. I think we would have bigger impact if this letter is
>> structured as a request for support (financial, etc) of a concrete action
>> that Open Source Pharma is ready to take:
>>
>> 1/ coordinate the crowd sourced selection of suitable compound(s)
>>
>> 2/ design a clinical study protocol for testing of the above
>>
>> I am putting together a draft proposal for Open Source Pharma to consider
>> Transparency Life Sciences for the execution of these crowdsourcing
>> efforts; I should have something out to all of you to review in the next
>> day or two.
>>
>>
>>
>> Regards,
>>
>> Tomasz
>>
>>
>>
>> On Fri, Aug 8, 2014 at 7:41 AM, Els Torreele <
>> els.torreele at opensocietyfoundations.org> wrote:
>>
>> So Ebola was just declared a public health emergency by WHO.
>>
>>
>>
>> Considering the call by Jeremy Farrar (Welcome Trust), Peter Piot (London
>> School) and David Heymann (ex-WHO, now UK Health Protection Agency) to test
>> experimental treatments now (and not only on Americans) and to do so with
>> public money and leadership (not waiting for companies to develop their own
>> drugs the normal and slow way),
>>
>> (see
>> http://online.wsj.com/articles/experimental-medicine-and-african-ebola-1407258551),
>>
>> could we write an open letter to Farrar, Piot and Heymann and
>> proposing/demanding that this be done in an open source approach, sharing
>> all data, crowdsourcing for more data and ideas, and possibly get more and
>> more researchers on it?
>>
>> The Welcome Trust and London School are likely supportive of an open
>> approach, and Farrar and co. could possibly be approached beforehand to
>> seek their support.
>>
>>
>>
>> I'm not a good writer, but I'm sure one or several of you could develop
>> such a letter quickly, and then we can get it out early next week, before
>> WHO convenes that medical ethics expert committee to discuss the ethics of
>> the accelerated clinical research (in which data sharing could be an
>> important element)
>>
>>
>>
>> What do people think?
>>
>>
>>
>>
>>
>>
>>  ------------------------------
>>
>> *From:* opensourcepharma [opensourcepharma-bounces at lists.okfn.org] on
>> behalf of Matthew Todd [mattoddchem at gmail.com]
>> *Sent:* Thursday, August 07, 2014 6:03 PM
>> *To:* opensourcepharma at lists.okfn.org
>> *Subject:* Re: [opensourcepharma] a open source cure for Ebola?
>>
>> I had an interesting day today giving a talk at Boston University. They
>> have a former NIH-supported compound collection (
>> http://cmld.bu.edu/science/compoundlibraries/). If a suitable bio lab
>> could be found for an Ebola screen, they would be interested in
>> contributing their whole collection to a screening effort in the short
>> term, open source. This is great.
>>
>> The compounds are not a repurposing library, but have interesting and
>> diverse chemotypes. I wonder if we can use this pledge to obtain
>> contributions from other labs, but before I start asking, I guess we need
>> to know (John M) whether there are the facilities to handle such a screen
>> anywhere? We're starting to talk thousands of compounds.
>>
>> Gordon Conference: That's great news, John. I was just looking at their
>> rules yesterday. They don't do "policy" conferences, but the easy thing to
>> do there is to ensure the talks are on science, but to qualify they need to
>> be run open source, at least to some extent. It'd be really interesting to
>> pull that program together. Let me know (offline if you prefer) if I can
>> help.
>>
>> Best,
>> M
>>
>>
>>
>>
>>
>> On 7 August 2014 09:57, McKew, John (NIH/NCATS) [E] <john.mckew at nih.gov>
>> wrote:
>>
>> Just getting caught here as I was away at a Gordon conference this week.
>>  I like the idea of crowd sourcing information using a Wiki format.  I can
>> contact NIAID and see what resources they are deploying or gathered.  I
>> will have to read through The papers Bernard has cited to see what was
>> screened to find these compounds. I would guess nobody has screened a
>> repurposing collection as large as the one we have so that might be worth
>> doing.  The catch is this must be BSL4 level of containment and our
>> facility can only go to BSL 2. NIAID has a faculty for BSL3 and. 4
>> screening so that would be an option.  When I get back to the office I will
>> look into how interested people are in this.  When people were coming down
>> with CM after IT injection of steroids contaminated with fungus we were
>> able to complete a screen and release data in a publication in about 3
>> months from outbreak.  In that case we did not find anything new.
>>
>> On another note I introduced the concept of a Gordon Med Chem session on
>> Open Source  Drug Discovery and Development at the planning session last
>> night.  At first the idea was met with complete silence but after I sold it
>> to the group I was able to gain enough enthusiasm to get this accepted into
>> the next stage of decision making.  I will let everyone what I hear next.
>>  As Matt mentioned at Bellagio this is primarily a very conservative group
>> of med chemists so this was a nice surprise.
>> John
>>
>> Sent from my iPhone
>>
>>
>>
>>
>>
>> MATTHEW TODD | Associate Professor
>> School of Chemistry | Faculty of Science
>>
>> THE UNIVERSITY OF SYDNEY
>> Rm 519, F11 | The University of Sydney | NSW | 2006
>>
>> T +61 2 9351 2180<tel:%2B61%202%209351%202180 <%2B61%202%209351%202180>>
>>  | F +61 2 9351 3329<tel:%2B61%202%209351%203329
>> <%2B61%202%209351%203329>>  | M +61 415 274104<tel:%2B61%20415%20274104
>> <%2B61%20415%20274104>>
>> E matthew.todd at sydney.edu.au<mailto:matthew.todd at sydney.edu.au> | W
>> http://sydney.edu.au/science/chemistry/research/todd.html | W
>> http://opensourcemalaria.org/
>>
>>
>> CRICOS 00026A
>> This email plus any attachments to it are confidential. Any unauthorised
>> use is strictly prohibited. If you receive this email in error, please
>> delete it and any attachments.
>>
>> _______________________________________________
>> opensourcepharma mailing list
>>
>> opensourcepharma at lists.okfn.org<mailto:opensourcepharma at lists.okfn.org>
>> https://lists.okfn.org/mailman/listinfo/opensourcepharma
>>
>>
>>
>> --
>> Follow me on Forbes<http://blogs.forbes.com/bernardmunos/> and
>> Fastercures<
>> http://fastercures.tumblr.com/post/62722481036/give-me-your-innovators-yearning-to-breathe-free#
>> <http://fastercures.tumblr.com/post/62722481036/give-me-your-innovators-yearning-to-breathe-free>
>> !>
>> _______________________________________________
>> opensourcepharma mailing list
>> opensourcepharma at lists.okfn.org<mailto:opensourcepharma at lists.okfn.org>
>> https://lists.okfn.org/mailman/listinfo/opensourcepharma
>>
>> _______________________________________________
>> opensourcepharma mailing list
>> opensourcepharma at lists.okfn.org
>> https://lists.okfn.org/mailman/listinfo/opensourcepharma
>>
>>
>>
>>
>> --
>>
>> MATTHEW TODD | Associate Professor
>> School of Chemistry | Faculty of Science
>>
>> THE UNIVERSITY OF SYDNEY
>> Rm 519, F11 | The University of Sydney | NSW | 2006
>> T +61 2 9351 2180  | F +61 2 9351 3329  | M +61 415 274104
>> E matthew.todd at sydney.edu.au | W
>> http://sydney.edu.au/science/chemistry/research/todd.html | W
>> http://opensourcemalaria.org/
>>
>> CRICOS 00026A
>> This email plus any attachments to it are confidential. Any unauthorised
>> use is strictly prohibited. If you receive this email in error, please
>> delete it and any attachments.
>>
>>
>> _______________________________________________
>> opensourcepharma mailing list
>> opensourcepharma at lists.okfn.org
>> https://lists.okfn.org/mailman/listinfo/opensourcepharma
>>
>>
>>
>>
>> _______________________________________________
>> opensourcepharma mailing list
>> opensourcepharma at lists.okfn.org
>> https://lists.okfn.org/mailman/listinfo/opensourcepharma
>>
>>
>>
>
>
> _______________________________________________
> opensourcepharma mailing list
> opensourcepharma at lists.okfn.org
> https://lists.okfn.org/mailman/listinfo/opensourcepharma
>
>

-- 
 JALEEL
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.okfn.org/pipermail/opensourcepharma/attachments/20140813/139b6542/attachment-0002.html>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: image001.gif
Type: image/gif
Size: 1556 bytes
Desc: not available
URL: <http://lists.okfn.org/pipermail/opensourcepharma/attachments/20140813/139b6542/attachment-0002.gif>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: image002.jpg
Type: image/jpeg
Size: 871 bytes
Desc: not available
URL: <http://lists.okfn.org/pipermail/opensourcepharma/attachments/20140813/139b6542/attachment-0002.jpg>